Pfizer calls on UK tribunal to overturn excessive pricing fine
Pfizer has urged the UK’s specialist competition tribunal to overturn a £63 million excessive pricing sanction, arguing that there was “nothing unfair” with how it priced an anti-epilepsy drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.